Table 3 Summary of clinicopathological characteristics of the clinical studies of CRC patients included in the meta-analysis
Authors, year (Country) | Method | Isoform | Cut-of value | Localization | Sample size (n) | Age Mean/med | Gender (M/F) | TNM stage | Outcome | NOS score# |
|---|---|---|---|---|---|---|---|---|---|---|
Gao, T. 2016 (China) | IHC | DCLK1-L/S | H-score | Cytoplasmic | 71 | 60 | 44/27 | I–IV | CSS | 8 |
Harada, Y. 2018 (Japan) | IHC | DCLK1-L /S | H-score | Cytoplasmic | 36 | 62.4 |  | I–III | CSS/RFS | 7 |
Makino, S. 2020 (Japan) | IHC | DCLK1-L /S | H-Score | Cytoplasmic | 180 | 61 | 120/60 | 0–IV | OS/RFS | 7 |
Dai, T. 2018 (China) | IHC | DCLK1-L | H-score | Cytoplasmic | 100 | 65 | 53/44 | I–IV | N/A | 6 |
Ikezono, Y. 2015 (Japan) | IHC | DCLK1-L | H-Score | Cytoplasmic | 18 | 51 | 9/9 | N/A | N/A | 6 |
Sarkar, S. 2017 (USA) | qRT-PCR | DCLK1-S | Image | Cytoplasmic/membranous/nucleous | 92 | 67 | 57/35 | I–IV | OS/ DFS | 7 |
Gagliardi, G. 2012 (USA) | IHC | DCLK1-L | H-score | Cytoplasmic | 71 | 58 | 38/20 | I–IV | CSS | 9 |
Razi, S. 2020 (Iran) | IHC | DCLK1-L/S | H-score | Cytoplasmic | 181 | 60 | 87/93 | I–IV | N/A | 7 |
Kalantari, E. 2021 (Iran) | IHC | DCLK1-S | H-score | Cytoplasmic | 235 | 60 | 177/165 | N/A | DSS/PFS | 7 |
Kang, X. 2020 (China) | IHC | DCLK1-L/S | H-score | Cell membrane | 92 | 49 | 52/40 | II–III | OS/PFS | 6 |